Tesamorelin + Ipamorelin
A stabilized GHRH analog paired with a selective ghrelin-receptor agonist for dual-pathway endocrine research.
01At a Glance
| Compound | Tesamorelin + Ipamorelin |
| Classification | Endocrine research compound |
| Constituents | Tesamorelin 5 mg — 5,135.9 g/mol Ipamorelin 5 mg — 711.85 g/mol |
| Molecular weight | Blend — see constituents |
| Sequence / Form | Tesamorelin 5 mg · Ipamorelin 5 mg |
| Purity | ≥98% HPLC, identity verified by mass spectrometry |
| Documentation | Batch-specific Certificate of Analysis available |
| Appearance | White lyophilized powder |
| Storage | Store sealed at 2–8°C. Long-term storage per certificate guidance. |
| Use | Research Use Only. Not for human or veterinary use. |
02Mechanism of Action
Tesamorelin is a trans-3-hexenoyl derivative of human GHRH(1-44), a modification studied for its resistance to dipeptidyl peptidase-4 degradation relative to native GHRH. It is investigated at the GHRH receptor.
Ipamorelin acts at the growth-hormone secretagogue receptor and is characterised in the literature for receptor selectivity.
This pairing differs from the CJC-1295 combination in the GHRH component: Tesamorelin is the full 1-44 sequence with an acyl modification, where CJC-1295 is a 1-29 fragment analog. Research compares the two GHRH strategies under identical secretagogue co-stimulation.
Research framing only · No human-use claims
03Research Context
- Dual-pathway somatotroph signaling assays
- DPP-4 resistance and peptide-stability studies
- GHRH analog comparison research
- Receptor co-stimulation models
04Quality & Verification
Ethos Bio presents compound information with an emphasis on identity verification, purity analysis, certificate access, and storage guidance. Product-specific documentation is available through the certificate page where applicable. Cold-chain shipping is available where required, and inventory is held under refrigerated conditions at our fulfillment center with temperature-logging protocols in place.
05FAQ
What is in this blend?
A single lyophilized vial containing Tesamorelin 5 mg and Ipamorelin 5 mg — 10 mg total peptide content.
How does this differ from CJC-1295 + Ipamorelin?
The GHRH component. Tesamorelin is an acyl-modified full GHRH(1-44) sequence studied for DPP-4 resistance; CJC-1295 is a modified GHRH(1-29) fragment. The Ipamorelin component is identical.
What is the total peptide content?
10 mg per vial — 5 mg of each constituent. Supplier specification states a 3 mL vial; confirm against the lot certificate.
How should Tesamorelin + Ipamorelin be stored?
Tesamorelin + Ipamorelin ships lyophilized and should be handled per standard research-peptide practice — kept cold, protected from light and moisture, and reconstituted only for laboratory use. Cold-chain handling is used where required. For research use only.
Is Tesamorelin + Ipamorelin approved for human use?
No. Tesamorelin + Ipamorelin is sold strictly for laboratory research use only and is not a drug or supplement. It is not approved for human or veterinary use or consumption.
How is Tesamorelin + Ipamorelin tested at Ethos Bio?
Every lot is independently verified by Kovera Labs on a third-party analytical panel — RP-HPLC purity and HPLC-MS identity confirmation — and a lot-specific certificate of analysis issued to Ethos Bio ships with the vial. See How We Test for the full methodology.